首页> 美国卫生研究院文献>Nephrology Dialysis Transplantation >A phase 3 multicentre randomized double-blind placebo-controlled parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416) a novel intravenous calcimimetic for secondary hyperparathyroidism in Japanese haemodialysis patients

【2h】

A phase 3 multicentre randomized double-blind placebo-controlled parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416) a novel intravenous calcimimetic for secondary hyperparathyroidism in Japanese haemodialysis patients

机译：一项三期多中心随机双盲安慰剂对照平行组研究用于评估新型静脉拟钙剂ecalccalcetide（ONO-5163 / AMG 416）对日本血液透析患者继发性甲状旁腺功能亢进的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundSecondary hyperparathyroidism (SHPT) is a major complication associated with chronic kidney disease. We evaluated the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, in Japanese haemodialysis patients with SHPT.

机译：背景继发性甲状旁腺功能亢进症（SHPT）是与慢性肾脏疾病相关的主要并发症。我们评估了新型静脉拟钙剂ecalccalcetide（ONO-5163 / AMG 416）在日本SHPT血液透析患者中的疗效和安全性。

著录项

期刊名称 Nephrology Dialysis Transplantation
作者
Masafumi Fukagawa; Keitaro Yokoyama; Takashi Shigematsu; Takashi Akiba; Akifumi Fujii; Takuto Kuramoto; Motoi Odani; Tadao Akizawa;
展开▼
作者单位

展开▼
年(卷),期 -1(32),10
年度 -1
页码 1723–1730
总页数 8
原文格式 PDF
正文语种
中图分类泌尿科学（泌尿生殖系疾病）;小儿泌尿科学;肾疾病;移植;
关键词
calcium-sensing receptor agonist (calcimimetics) etelcalcetide (ONO-5163/AMG 416) placebo-controlled phase 3 study secondary hyperparathyroidism CKD-MBD;

机译：钙敏感受体激动剂（拟钙剂）;依卡西肽（ONO-5163 / AMG 416）;安慰剂对照的3期研究;继发性甲状旁腺功能亢进;CKD-MBD;

相似文献

外文文献
中文文献

1. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients [J] . Yokoyama Keitaro, Fukagawa Masafumi, Shigematsu Takashi, Clinical nephrology . 2017,第2期

机译：一种12周的剂量升级的精体升级（ONO-5163 / AMG 416），一种新的静脉内钙化，用于日本血液透析患者的继发性甲状旁腺功能亢进症
2. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients [J] . Bell Gregory, Huang Saling, Martin Kevin J., Current medical research and opinion . 2015,第5期

机译：一项随机，双盲，2期临床研究，评估AMG 416在血液透析患者中继发性甲状旁腺功能亢进的安全性和疗效
3. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial [J] . Yeming Wang, Fei Zhou, Dingyu Zhang, Trials . 2020,第1期

机译：评估静脉内雷达维尔在成人患者中严重Covid-19的疗效和安全性：研究方案3阶段随机，双盲，安慰剂控制，多期式试验
4. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study [O] . Tadao Akizawa, Ryutaro Shimazaki, Masafumi Fukagawa 2012

机译：在接受血液透析的日本继发性甲状旁腺功能亢进患者中，新型拟钙剂evocalcet（KHK7580）的2b期研究：一项随机，双盲，安慰剂对照的剂量查找研究
5. MP361EFFICACY AND SAFETY OF A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE) IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM : RESULTS OF A PLACEBO CONTROLLED PHASE III STUDY [O] . Masafumi Fukagawa, Keitaro Yokoyama, Takashi Shigematsu, 2016

机译：新型静脉注射钙质，ONO-5163（Etelcalcetide）在日本血液透析患者中的新型静脉注射患者的MP36减少和安全性：安慰剂控制第三阶段研究的结果

A phase 3 multicentre randomized double-blind placebo-controlled parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416) a novel intravenous calcimimetic for secondary hyperparathyroidism in Japanese haemodialysis patients

摘要

著录项

相似文献

相关主题

期刊订阅